Angiotensin receptor blockers (ARBs) are available in different dosages and it is common clinical practice to uptitrate if blood pressure goal is not achieved with the initial dose. Data on the incremental antihypertensive efficacy with uptitration are scarce. It is also unclear if antihypertensive efficacy of losartan is comparable with other ARBs.
Introduction
Hypertension is an asymptomatic condition and should remain so when treated. Angiotensin receptor blockers (ARBs) are known to provide a good blood pressure reduction with little, if any, adverse effects. 1 The magnitude and duration of antihypertensive response of various ARBs is thought to vary due to differences in pharmacokinetic and pharmacodynamic properties. 2 Conflicting results have been reported in several reviews and meta-analyses regarding the antihypertensive efficacy of various ARBs; some suggesting no difference within the class, 1, 3 whereas others suggesting losartan being inferior. 4, 5 Twentyfour hour ambulatory blood pressure (ABP) monitoring is considered as the most objective and accurate tool to assess antihypertensive efficacy and is shown to predict cardiovascular events even after adjusting for office blood pressure measurement. 6 Our objective was two-fold:
(i) to evaluate the antihypertensive efficacy of ARBs as assessed by 24 h ABP at 25% maximum (max), 50% max, and max dose, and (ii) to evaluate ABP reduction with losartan compared with other ARBs.
Methods

Search strategy
A systematic search was performed in PubMed, EMBASE, and Cochrane Central Register of Clinical Trials (Cochrane Library Issue 6, June 2012) using the key terms 'Angiotensin Receptor Blockers', 'ARBs', and names of all individual ARBs. We limited our search to randomized controlled trials in human subjects and in peer-reviewed journals until December 2012. No language restriction was applied. The reference lists of identified articles and bibliographies of original articles were also reviewed. Trials in the abstract form without a manuscript published were excluded for this analysis. Authors of the individual trials were contacted in case of inadequate data.
Selection criteria
To be included in the analysis, a trial had to fulfil the following criteria: (including other ARBs) or with placebo, (ii) patient population with hypertension, (iii) ARB used as monotherapy, (iv) no uptitration of ARB dose throughout the trial, and (v) trial duration of at least 4 weeks. Studies were excluded if ARB doses were uptitrated or if additional antihypertensive drugs were added to control the blood pressure. None of the included studies had patients with severe hypertension. Studies with tasosartan were excluded, since it was never marketed.
Data extraction
Two authors (H.M. and J.R.) searched the data independently and in duplicate. Disagreements were resolved by consensus. We extracted characteristics of each trial, duration of intervention and methods, baseline demographics, type of ARB used with the dose, 24 h ABP at baseline and after the intervention, for our analysis.
Quality assessment
The criteria used for quality assessment were sequence generation of allocation, allocation concealment, masking of participants, personnel, and outcome assessors, incomplete outcome data, selective outcome reporting, and other sources of bias, as recommended by the Cochrane Collaboration. 7 
Statistical analysis
The statistical analysis was done in line with recommendations from the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, 8 using Review
Manager (RevMan), version 5.1.7, the Cochrane Collaboration, 2012. Heterogeneity was assessed using the I 2 statistics. I 2 is the proportion of total variation observed between the trials attributable to differences between trials rather than sampling error (chance) and we considered I 2 , 25% as low and I 2 . 75% as high. Random-effects model of DerSimonian and Laird 9 was used to calculate the effect sizes if I 2 .
25%. Analysis was performed on intention-to-treat basis. Data from changes in baseline blood pressure were combined using weighted mean difference method. For trials that did not provide complete information about variance for net change in BP, the information was obtained from confidence intervals (CIs), P-value, or from t-statistics.
Variance was estimated from pre-test -post-test (parallel group and factorial design) and crossover designs as suggested by Follmann et al. 10 All the studies were stratified based on 25% max dose, 50% max dose, and the max dose of ARB as defined in hypertension guidelines of the Joint National Committee 11 ( Table 1) . Separate head-to head comparison was performed between losartan and other ARBs when data were available. Publication bias was estimated visually by funnel plots, and/or using Begg's test and the weighted regression test Figure 1 Selection of studies. ARBs, angiotensin receptor blockers. Figure 2 Antihypertensive efficacy of angiotensin receptor blockers at 25% maximum, 50% maximum, and the maximum dose. Error bars represent 95% confidence intervals. ABP, ambulatory blood pressure; n, number of patients; max, maximum.
of Egger et al. 12 Sensitivity analyses was performed for BP reduction at 50% max and max dose of ARBs based on the quality of study, mean baseline blood pressure (above vs. below mean BP), number of patients in the study (≤100 vs. .100), and study duration (≤8 vs. .8 weeks). We estimated difference between subgroups according to the tests of interaction. 13 
Results
Study characteristics
We identified 2684 articles, out of which 146 abstracts were retrieved and reviewed for possible inclusion. Sixty-two men) and the mean duration of 10 weeks fulfilled the inclusion criteria and were included in the analysis ( Table 2) . These 62 trials were with azilsartan (n ¼ 1), candesartan (n ¼ 8), eprosartan (n ¼ 1), irbesartan (n ¼ 6), losartan (n ¼ 25), olmesartan (n ¼ 12), telmisartan (n ¼ 14), and valsartan (n ¼ 12) ( Table 1) . Forty-six trials were excluded: uptitrated dose of ARBs (n ¼ 13), inadequate data (n ¼ 15), ARBs combined with other drugs (n ¼ 12), baseline study population without hypertension (n ¼ 3), and studies with tasosartan (n ¼ 3) (Figure 1) . All the included studies were done in patients with mild to moderate hypertension. Of the 62 trials, 18 trials reported adequate generation of allocation sequence and adequate allocation concealment, and 39 reported adequate masking of participants, Angiotensin receptor blockers and ambulatory blood pressure monitoring personnel, and outcome assessors. On the basis of quality assessment, 18 were deemed as low-bias risk trials and the rest as high-bias risk trials.
Antihypertensive efficacy of angiotensin receptor blockers
Reduction in blood pressure was measured at three separate doses-25% max dose, 50% max dose, and at the max dose for all the ARBs (Figure 2) .
Twenty-five per cent maximum dose of angiotensin receptor blockers Data were available from 12 studies with the total of 1253 patients. Reduction in BP was 10.3 mmHg (95% CI: 9.3 -11.3) systolic and 6.7 mmHg (95% CI: 5.8 -7.5) diastolic with 25% max dose of ARBs.
Fifty per cent maximum dose of angiotensin receptor blockers Data were available from 40 studies with the total of 4035 patients. With 50% max dose, the reduction in BP was 11.8 mmHg (95% CI: 10.8-12.7) systolic and 7.6 mmHg (95% CI: 7.0 -8.3) diastolic ( Figure 3) .
Maximum dose of angiotensin receptor blockers
Data were available from 30 studies with the total of 4025 patients. With the maximum dose of ARBs, the reduction in BP was 13.0 mmHg (95% CI: 11.8-14.3) systolic and 8.3 mmHg (95% CI: 7.6 -9.1) diastolic (Figure 4) .
On comparing ARBs at 25% max dose with 50% max dose, there was a significant reduction of systolic ABP (P ¼ 0.04), but not diastolic ABP (P ¼ 0.08). On comparing ARBs at 50% max dose with the max dose, there was no significant difference in both systolic (P ¼ 0.11) and diastolic (P ¼ 0.18) ABP reduction. There was a significant reduction in both systolic (P ¼ 0.0008) and diastolic ABP (P ¼ 0.004) when ARBs at 25% max dose were compared with the ARBs at the max dose, but the four-fold increase in dose resulted in a meagre 2.7 mmHg (mean) decrease in systolic pressure. Since this is an indirect comparison, the data should be interpreted with caution.
Comparison of losartan 50 and 100 mg with other angiotensin receptor blockers at 50% maximum dose and at maximum dose Head-to-head comparison between losartan and other ARBs was available in six studies ( Figure 5) . Losartan in the dose of 50 mg lowered ABP less well than other ARBs at 50% max dose by 2.5 mmHg systolic (P , 0.0001) and 1.8 mmHg diastolic (P ¼ 0.0003). Losartan in the dose of 100 mg lowered ABP less well than other ARBs at max dose by 3.9 mmHg systolic (P ¼ 0.0002) and 2.2 mmHg diastolic (P ¼ 0.002) ( Figure 5 ).
Significant heterogeneity was found to be present in most of the analyses and hence random variance model was used. There was no evidence of publication bias for any of the analyses. Sensitivity analysis performed to evaluate the role of baseline blood pressure on BP reduction showed no significant difference between the two subgroups (above vs. below mean BP) ( Table 3) . Similarly sensitivity analyses for various subgroups based on the risk of bias, number of patients, and study duration did not make any noticeable difference to any of the outcomes (data not shown).
Discussion
In the present analysis of the antihypertensive efficacy of various ARBs with 24 h ABP monitoring, we observed a shallow dose- Interaction P-value comparing reduction in BP above and below baseline mean BP. BP, blood pressure; CI, confidence interval; max, maximum; SD, standard deviation response curve. Doubling the dose is a common clinical practice when proper blood pressure levels are not reached. In our analysis, doubling the dose merely increased the antihypertensive efficacy by ,2 mmHg systolic or diastolic. Losartan had a similarly shallow dose-response curve and, in head-to-head comparisons with other ARBs, was significantly less efficacious at all doses. The control of blood pressure in the USA remains far from adequate as was observed by the most recent NHANES data. 76 Thus, it becomes increasingly important to better control blood pressure with currently available drugs. Monotherapy remains the standard initial treatment for reducing blood pressure in many hypertensive patients. However, if specific blood pressure targets are not reached, most physicians will resort to uptitrating the drug to its max dose before switching to combination therapy. Indeed the American Joint National Committee VII 11 2012 recommend addition of drug from another class rather than uptitration for greater BP control. The guidelines also recommend treatment initiation with combination therapy in patients at high risk in whom early BP control is required. 79 In a meta-analysis of 354 trials, 80 reduction in blood pressure was only 20% lower with half standard dose compared with standard dose and was consistent among all antihypertensive agents. However, the dose-related adverse events were significantly lower with half standard dose compared with standard dose with thiazides, calcium channel blockers, and beta-blockers, but not with ACE-inhibitors and ARBs. 80 In the same meta-analysis, they showed that the reductions in BP were additive with low-dose combination therapy, but the adverse effects were less than additive compared with uptitration. 80 Several studies have shown that fixed combinations improve efficacy and adherence without increasing the overall adverse effects. 81 In a study comparing combination of valsartan and hydrochlorothiazide (HCTZ) with individual monotherapy, reduction in SBP/DBP was 16.7/8.6 mmHg with combination compared with 14.2/7.9 mmHg with valsartan alone and 9.0/3.9 mmHg with HCTZ alone. 26 Similarly, in a study comparing combination of olmesartan and azelnidipine with individual monotherapy, reduction in SBP/DBP was 22.1/13.5 mmHg with combination compared with 12.1/6.9 mmHg with olmesartan and 12.0/6.9 mmHg with azelnidipine. 53 Thus, antihypertensive combination therapy may be considered over uptitration of a single agent for better hypertension management. Angiotensin receptor blockers are available in fixed combinations with thiazide diuretics (HCTZ and chlorthalidone) as well as with calcium channel blockers (amlodipine). Our analysis provides good evidence that antihypertensive efficacy of losartan is weaker compared with other ARBs and increasing the dosage from 50 to 100 mg contributes less to further BP reduction. The antihypertensive efficacy of losartan has been under fire ever since it was marketed. 82 Although all ARBs act by blocking angiotensin II receptor blocker, pharmacokinetic differences exist and may be the reason for the difference in antihypertensive efficacy. In a group of normotensive subjects comparing losartan with irbesartan and valsartan, losartan had the weakest angiotensin II antagonist effect; whereas irbesartan showed the slowest decay and longest duration of antagonist effects. 83, 84 At 4 h, losartan blocked 43% of angiotensin II-induced systolic BP increase, compared with 51% with valsartan and 88% with irbesartan. 84 The results were similar when angiotensin II receptor blockade was assessed by the reactive rise in plasma angiotensin II levels and with an in vitro receptor assay. 84 In several head-to-head comparisons with other ARBs and meta-analyses, losartan lowered the blood pressure less well than other ARBs; however, for office blood pressure, this may be of questionable significance. 1 Its dose-response curve was so shallow that it was initially marketed in one dose only, and instead of uptitration from 50 to 100 mg, add-on therapy with HCTZ was advised.
Limitations
As with other meta-analyses, given the lack of data in each trial, we did not adjust our analysis for adherence to therapy. Also, the results are subject to limitations inherent to any meta-analysis based on pooling of data from different trials with different duration and different patient groups. We tried to minimize the effect of other antihypertensive drugs by excluding the studies that had second-or third-line agents added to control high BP. We also excluded studies that uptitrated the dose of ARB, since this study aimed at measuring 24 h BP at specifically 25% max, 50% max, and at the max dose. Blood pressure response to any drug depends on baseline blood pressure. However, we included only a rather homogeneous patient population with mild to moderate hypertension. Sensitivity analysis comparing studies with above baseline BP with those below baseline did not show a significant difference. Adequate data were not available to perform the head-to-head comparison between different ARBs except losartan.
Conclusion
As evaluated by 24 h ABP, uptitration of ARBs marginally enhances their antihypertensive efficacy. Antihypertensive efficacy of losartan at starting dose and at max dose is consistently inferior to other ARBs.
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